Diligence memo · auto-generated · as of July 2, 2026

Foment Bio, Inc.

Foment Bio, Inc. looks fair against its niche peers and is quiet on financing cadence.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

Foment Bio, Inc. operates in Pharmaceuticals, based in MONTGOMERY.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Foment Bio, Inc. has raised $543K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $543K on 2024-05-31.

Most recent recorded round closed around 2024-05-31.

Valuation (modeled)modeled

Provath models Foment Bio, Inc. at approximately $2.6M (range $304K–$8.9M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.01× the median modeled value of Pre-Seed Pharmaceuticals companies in 2022–2024 (38 peers) — value vs value, same stage and era. Within the normal band (101% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 2.1 yr ago; this sector typically re-raises about every 13 months.

Slightly overdue versus sector cadence.

Comparablesmixed

Capital scale ranks ahead of 13% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 5% of those peers.

Closest niche peers: Eleison Pharmaceuticals Inc, Telomir Pharmaceuticals, Inc., Drusolv Therapeutics, Inc., TF Tech Ventures, Inc., Thyron Pharmaceuticals, Inc..

Peoplefiled

2 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.